Drugs / CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Cell therapy targets CD19 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04484012 | Dec 2020 → Feb 2027 expected | mantle cell lymphoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04484012 ↗ |
| Action | Deplete | “These CD19-specific T cells may help the body's immune system identify and kill CD19 positive cancer cells.” NCT04484012 ↗ |
| Modality | Cell therapy | “CD19 chimeric antigen receptor (CAR) T cells” NCT04484012 ↗ |
| Route | Intravenous | “Patients also receive CD19 CAR T cells intravenously (IV) on day 0.” NCT04484012 ↗ |
| Target | CD19 | “recognize CD19” NCT04484012 ↗ |